$ICCM News
Last published 12h ago
- 12h agoICCMIceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026PR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...
- 2d agoICCMIceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP PortfolioPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology...
- 2w agoICCMIceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer CryoablationPR NewswireFirst patient enrolled and treated at West Cancer Center in Tennessee, USACAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the
- 1mo agoICCMIceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical SitePR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 2mo agoICCMIceCure Medical Receives Regulatory Approval to Market ProSense® in ChinaPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 2mo agoICCMIceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the NetherlandsPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 2mo agoICCMWest Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer CryoablationPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 3mo agoICCMIceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-YearPR NewswireThe Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA")
- 3mo agoICCMIceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation TreatmentPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 3mo agoICCMIceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026PR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 3mo agoICCMIceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®PR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 3mo agoICCMIceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical SitePR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 4mo agoICCMIceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® CryoablationPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based...
- 4mo agoICCMIceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast CancerPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 4mo agoICCMIceCure Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 4mo agoICCMIceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast CancerPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 4mo agoICCMIceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional InvestorPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 4mo agoCLPTICCMNTHIQUREBiotech's New Frontier: Companies Breaking Through Medicine's Toughest BarriersGlobeNewswireDENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene
- 4mo agoICCMIceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA ClearancePR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), today reported a 70% increase in its U.S. active commercial...
- 5mo agoICCMIceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq CompliancePR NewswireIceCure Medical Ltd. (the "Company" or "IceCure" or "IceCure Medical") (NASDAQ: ICCM), developer of minimally-invasive cryoablation technology that...
- 5mo agoICCMIceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class OverbookedPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 6mo agoICCMIceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 6mo agoICCMIceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North AmericaPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 6mo agoICCMIceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026PR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 6mo agoICCMIceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. MarketPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 6mo agoICCMIceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025PR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 7mo agoICCMIceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private PlacementPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 7mo agoICCMIceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free RatesPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 7mo agoICCMIceCure Appoints Meir Peleg as Chief Financial OfficerPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 7mo agoICCMIceCure Reports 2025 Full Year Financial & Operational ResultsPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 8mo agoICCMU.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast CancerPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 8mo agoICCMIceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026PR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 8mo agoICCMAmerican Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast CancerPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that...
- 8mo agoICCMIceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast FibroadenomasPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 8mo agoICCMIceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026PR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 8mo agoICCMIceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer CryoablationPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that...
- 9mo agoICCMIceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®PR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that...
- 9mo agoICCMIceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones AchievedPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that...
- 9mo agoICCMIceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast CancerPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that...
- 10mo agoICCMIceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® SalesPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 10mo agoICCMIceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast CancerPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 11mo agoICCMIceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual MeetingPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 11mo agoICCMIceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation OutcomesPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 11mo agoICCMIceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025PR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 11mo agoICCMIceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney CancerPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 12mo agoICCMIceCure Medical Announces Receipt of Nasdaq Minimum Bid Price NotificationPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an...
- 12mo agoICCMIceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025PR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 1y agoICCMIceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial TractionPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 1y agoICCMIceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year SurvivalPR NewswireIceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...
- 1y agoICCMIceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation AdvancesPR NewswireIceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...